Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.38 and last traded at C$0.40, with a volume of 72738 shares. The stock had previously closed at C$0.41.
Medicenna Therapeutics Price Performance
The firm has a market capitalization of C$32.95 million, a price-to-earnings ratio of -2.63 and a beta of 2.89. The company has a debt-to-equity ratio of 4.79, a quick ratio of 4.65 and a current ratio of 1.52. The business’s 50 day moving average is C$0.49 and its 200-day moving average is C$0.72.
Medicenna Therapeutics (TSE:MDNA – Get Free Report) last released its earnings results on Thursday, June 25th. The company reported C($0.05) earnings per share for the quarter. Medicenna Therapeutics had a negative return on equity of 219.30% and a negative net margin of 533,640.00%. Equities analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 EPS for the current fiscal year.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
